Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli Lilly began marketing its rival product Mounjaro in the world's most ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination therapy might change that.

As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy. | As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy ...

Biocon is set to launch generic versions of Wegovy in India and Canada, aiming for market entry by late 2026 or early 2027.

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

But Lilly’s Zepbound therapy outstripped Wegovy in weekly new prescriptions this year as Novo struggles to convince investors it can remain competitive amid the weight loss drug boom.